A venture capital firm based in Canada is making investments out of its first fund which closed at $500M. The fund was jointly established with a leading Chinese investment bank. The firm usually makes initial investments in the range of $5M-$10M with additional capital reserved for follow-on investments, but is capable of making smaller or larger investments. The firm primarily makes straight equity investments, but may consider convertible notes for smaller/earlier rounds. On occasion, public companies may be considered for investment. The firm is open to opportunities globally and will lead rounds as well as co-invest in a syndicate. The firm has no set number of investments it makes per year, but is a relatively nimble firm and able to act quickly when an opportunity presents itself.
The firm’s focus is in health sciences, including therapeutics, devices, diagnostics and health IT. Generally, the firm focuses on assets with clinical data and will invest in up unto Ph. III. The firm will evaluate pre-clinical assets pending there is a strong scientific rationale, and tends to prioritize platform technologies for early-stage assets. As for medical device companies, the firm prefers to see products with clinical data.
The firm prefers to work with experienced management teams, but will consider first time entrepreneurs as well. The firm typically seeks a board seat along with investment and in addition to capital, seeks to add value through developmental, infrastructure and expertise support, as needed, through the firm’s global network. The firm’s approach is to establish long-term relationships with target companies, with a view to enable and strengthen management to realize the full potential and value of the technology.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 